title: Detrimental effects of N-acetylcysteine plus desferoxamine combination in an experimental nephrotic syndrome model.
abstract: The aim of this study was to evaluate the effects of N-acetylcysteine (NAC) and desferoxamine (DFO) administered alone or in combination together in rats with doxorubicin (DOX)-induced nephrotic syndrome, by monitoring oxidative stress parameters and trace elements in renal tissue and erythrocytes. Fifty-four male Sprague-Dawley rats were included the study. Equal volume of isotonic saline was injected to control rats. After DOX administration, the animals were divided into four experimental groups: (a) rats given only DOX; (b) rats treated with NAC; (c) rats treated with DFO; (d) rats treated with NAC plus DFO. The combination of N-acetylcysteine and DFO has no beneficial effect on reducing proteinuria in experimentally nephrotic rats, although both of these agents ameliorate the condition when administered separately. It seems likely that detrimental effects of NAC plus DFO could be secondary to its effects on erythrocyte selenium levels demonstrated here. Consequently, the results may propose caution to the use of antioxidant therapeutic strategies such as NAC plus DFO against nephropathy.
authors: Department of Internal Medicine, Gülhane Military Medical Academy, Ankara, Turkey.
authors: F
authors: F
authors: Bulucu
authors: C
authors: C
authors: Oktenli
authors: L
authors: L
authors: Kenar
authors: B
authors: B
authors: Koc
authors: R
authors: R
authors: Ocal
authors: N
authors: N
authors: Karadurmus
authors: V
authors: V
authors: Inal
authors: L
authors: L
authors: Yamanel
authors: Y S
authors: YS
authors: Sanisoglu
authors: A
authors: A
authors: Aydin
mesh_terms: D000111:Acetylcysteine / Q000009:adverse effects* / Q000627:therapeutic use; D000818:Animals; D000975:Antioxidants / Q000009:adverse effects* / Q000627:therapeutic use; D002374:Catalase / Q000097:blood / Q000378:metabolism; D003300:Copper / Q000097:blood; D003676:Deferoxamine / Q000009:adverse effects* / Q000627:therapeutic use; D004317:Doxorubicin; D004359:Drug Therapy, Combination; D005979:Glutathione Peroxidase / Q000097:blood / Q000378:metabolism; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009404:Nephrotic Syndrome / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012643:Selenium / Q000097:blood; D013482:Superoxide Dismutase / Q000097:blood / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D015032:Zinc / Q000097:blood / Q000378:metabolism
chemical_list: D000975:Antioxidants; D017392:Thiobarbituric Acid Reactive Substances; D003300:Copper; D004317:Doxorubicin; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D012643:Selenium; D003676:Deferoxamine; D015032:Zinc; D000111:Acetylcysteine